IMPROVING HEALTH THROUGH TRANSFORMATIVE THERAPIES AND DISRUPTIVE TECHNOLOGIES

Hatteras’ mission is to build transformational human medicine companies that benefit patients and the professionals who serve them.

STRIDEBIO

Developing engineered viral vectors for gene therapy using structure-inspired design of adeno-aden-associated virus (AAV) vectors that can evade neutralizing antibodies, a current limitation of existing gene therapies.

VIEW PORTFOLIO

G1 THERAPEUTICS

A clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.

VIEW PORTFOLIO

DROPWORKS

Developing a fast, easy-to-use, and cost accessible digital PCR platform for DNA and RNA quantification.

VIEW PORTFOLIO

ELLIGO HEALTH RESEARCH

Providing on-demand clinical research infrastructure to enable large physician practices to offer clinical trial participation to their clients.

VIEW PORTFOLIO

RIBOMETRIX

Developing small molecules that target functional 3D RNA structures to treat human disease.

VIEW PORTFOLIO

CONTEGO MEDICAL

Developing an integrated embolic protection platform to improve the safety and efficacy of catheter-based interventions.

VIEW PORTFOLIO

ORIG3N

Offering a full line of DNA tests to give you a new insight into what makes you unique.

VIEW PORTFOLIO

GRAYBUG

Developing injectable therapeutics to reduce the burden of treating vision-threatening diseases.

VIEW PORTFOLIO

QVELLA

Developing a platform for the rapid detection of pathogens causing Sepsis.

VIEW PORTFOLIO

STANDARD BARIATRICS

Developing a new standard in the surgical treatment of obesity.

VIEW PORTFOLIO